Zovaglutide dose 2

Phase 3

BBeijing QL Biopharmaceutical Co.,Ltd

Zovaglutide dose 2 is one of 4 therapeutic programs targeting Overweight , Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight , ObesityActive, not recruiting

Overweight , ObesityPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Overweight , Obesity

#DrugCompanyPhaseTrials

Mwn109 1

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 2

Mwn109 2

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 3

Mwn109 3

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

5 4

Zovaglutide dose 2

BBeijing QL Biopharmaceutical Co.,Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Overweight , Obesity

NCT07230119

Clinical

Trials by Indication[1]

Overweight , Obesity1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.

Active, not recruiting·BBeijing QL Biopharmaceutical Co.,Ltd·Phase 3·NCT07230119·755 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zovaglutide dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Zovaglutide dose 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Beijing QL Biopharmaceutical Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: BBeijing QL Biopharmaceutical Co.,Ltd

Zovaglutide dose 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Overweight , Obesity1 trial

References

Drug Info

Quick Facts

Related News